Announcements
The new Eurosurveillance website is almost here.

Eurosurveillance is on the updated list of the Directory of Open Access Journals and in the SHERPA/RoMEO database. Read more here.

On 6 June 2017, the World Health Organization (WHO) published updates to its ‘Essential Medicines List’ (EML). Read more here.

Follow Eurosurveillance on Twitter: @Eurosurveillanc


In this issue


Home Eurosurveillance Edition  2017: Volume 22/ Issue 16 Article 1
Back to Table of Contents
Download (pdf)
Next

Eurosurveillance, Volume 22, Issue 16, 20 April 2017
Rapid communication
Corbella, Mariani, Ferrari, Comandatore, Scaltriti, Marone, and Cambieri: Three cases of mcr-1-positive colistin-resistant Escherichia coli bloodstream infections in Italy, August 2016 to January 2017

+ Author affiliations


Citation style for this article: Corbella M, Mariani B, Ferrari C, Comandatore F, Scaltriti E, Marone P, Cambieri P. Three cases of mcr-1-positive colistin-resistant Escherichia coli bloodstream infections in Italy, August 2016 to January 2017. Euro Surveill. 2017;22(16):pii=30517. DOI: http://dx.doi.org/10.2807/1560-7917.ES.2017.22.16.30517

Received:28 March 2017; Accepted:20 April 2017


A new plasmid-mediated transferable resistance determinant, the mcr-1 gene, encoding a phosphoetha-nolamine transferase, has been described in November 2015 by Liu et al. for the first time [1,2]. The plasmid carrying mcr-1 is mobilised to an Escherichia coli recipient by conjugation [1,2]. Since that description, the mcr-1 gene has been detected in isolates recovered from animals, in the food chain and in humans in many countries in Europe and in many other areas worldwide [3-8].

Here we describe three cases of human bloodstream infection in Italy caused by E. coli harbouring the mcr-1 gene. All three patients were hospitalised in a 1,000-bed hospital, in Pavia, in the period between August 2016 and January 2017.

Case description

Case 1

In July 2016, a woman in her 70s with a pancreatic ductal carcinoma diagnosed 5 years earlier, was admitted in a respiratory disease unit for pleural effusion. It was known that she had bone and liver metastases, was splenectomised, and had received 18 chemotherapy cycles in the previous 5 years. Four days after admission she experienced fever (38.8° C), vomiting and abdominal pain associated with increased inflammatory markers: procalcitonin 60 ng/mL (norm: 0.00–0.50 ng/mL), C-reactive protein (CRP) 23.29 mg/dL (norm: 0.00–0.50 mg/dL) and highly elevated white blood cells (WBC) 38.92 x 103 uL (norm: 4–10 x 103 uL). E. coli was isolated from urine and blood cultures. The two isolates showed the same antimicrobial susceptibility profiles. Both showed resistance to colistin. The susceptibly profile of the isolate obtained from blood is shown in the Table.

Table

Antibiotic susceptibility according to European Committee on Antimicrobial Susceptibility Testing (EUCAST) clinical breakpoints [9] of clinical Eschericha coli isolates obtained from human cases with bloodstream infections, Pavia, Italy, August 2016–January 2017 (n = 3 cases)

MIC mg/L (S/I/R)
Case Isolation date Sequence type     CST     AMK     AMP     CAZ     CTX     FEP     CIP     FOS       MEM     GEN       TZP       SXT     TGC
Case 1 7 Aug 2016 131 4 (R) < 4 (S) ≤ 2 (S) ≤ 0.5 (S) ≤ 1 (S) ≤ 1 (S) ≤ 0.25 (S) ≤ 16 (S) ≤ 0.125 (S) ≤ 1 (S) ≤ 4/4 (S) ≤ 1/19 (S) ≤ 0.5 (S)
Case 2 12 Aug 2016 3941 4 (R) < 4 (S) > 8 (R) ≤ 0.5 (S) ≤ 1 (S) ≤ 1 (S) > 1 (R) ≤ 16 (S) ≤ 0.125 (S) > 4 (R) ≤ 4/4 (S) > 4/76 (R) ≤ 0.5 (S)
Case 3 22 Jan 2017 1851 4 (R) < 4 (S) > 8 (R) ≤ 0.5 (S) ≤ 1 (S) ≤ 1 (S) ≤ 0.25 (S) ≤ 16 (S) ≤ 0.125 (S) ≤ 1 (S) ≤ 4/4 (S) > 4/76 (R) ≤ 0.5 (S)

AMK: amikacin; AMP: ampicillin; CAZ: ceftazidime; CIP: ciprofloxacin; CST: colistin; CTX: cefotaxime; FEP: cefepime; FOS: fosfomycin; GEN: gentamicin; I: intermediate; MEM: meropenem; MIC: minimum inhibitory concentration; R: resistant; S: susceptible; SXT: trimethoprim-sulfamethoxazole; TGC: tigecycline; TZP: piperacillin–tazobactam.

The patient was empirically treated with meropenem intravenously and her clinical condition rapidly improved. She was discharged after 20 days of hospitalisation. She had never received previous treatment with colistin and did not report any previous close contacts with farm animals. She had not travelled abroad since 2008.

Case 2

In August 2016, a woman in her mid-60 with a diagnosis of non-Hodgkin’s Lymphoma was admitted at the haematological unit of our hospital for distention of the ureter, renal pelvis and calices due to blockage of urine flow by bulky lymph nodes. She had been treated with two cycles of chemotherapy in the previous 6 weeks with poor response. She underwent nephrostomy after admission and one day later she developed fever (38.0° C) and chills. She had a severe pancytopenia with less than 0.800 x 103/uL (norm: 4–10 x 103 uL) WBC and increase of CRP 3.50 mg/dL (0.00–0.50 mg/dL).

The patient received intravenous empirical treatment with piperacillin/tazobactam and vancomycin. E. coli was isolated from urine and blood cultures. As with Case 1, the two isolates obtained showed the same antimicrobial susceptibility profiles, both indicating resistance to colistin. The susceptibility profile of the isolate obtained from blood is shown in the Table.

The CRP decreased to normal range within 3 days and the fever disappeared within 24 hours. The patient died 5 days later due to a massive cerebral haemorrhage. She had never received previous treatment with colistin and did not report any previous close contact with farm animals. In the previous 12 years she had not travelled abroad.

Case 3

In January 2017, a woman in her early 80s with fever (> 38.5° C), diarrhoea and abdominal pain was admitted at the infectious diseases unit of the same tertiary hospital. In 2012, she underwent mastectomy and chemotherapy for breast cancer. Blood cultures were drawn upon admission and she received intravenous empirical treatment with piperacillin/tazobactam. E. coli was isolated from blood cultures. The Table shows the antimicrobial profile; the strain was colistin-resistant but susceptible to other commonly used antimicrobials (Table). She had 10.03 x 103/uL WBC (norm: 4–10 x 03 uL) and high inflammatory markers: procalcitonin 50.50 ng/mL (norm: 0.00–0.5 ng/mL), CRP 28.41 mg/dL (norm: 0.00–0.5 mg/dL).

Her clinical condition rapidly improved and she was discharged from hospital after 8 days. She had never been treated with colistin, did not report any previous close contact with farm animals and she had never travelled abroad.

Microbiological findings

Blood samples for cultures were collected in BD BACTEC culture aerobic/anaerobic vials and were incubated into BACTEC FX automated blood culture system (Becton Dickinson and Company, Franklin Lakes, New Jersey, United States), according to the manufacturer’s instructions.

Positive blood cultures were subjected to Gram-staining and subcultured into aerobic sheep blood agar plates, chocolate agar plates, selective plates and into Schaedler agar and 5% sheep blood plates (bioMérieux SA, Marcy-l’Etoile, France) anaerobically and incubated at 37°C overnight: the organisms were identified by Matrix-Assisted Laser Desorption Ionization time-of-flight (MALDI-TOF) (Bruker Daltonics GmbH, Bremen, Germany).

The isolates were tested for antimicrobial susceptibility using Phoenix 100 (BD) automated system N-MIC panel. Isolates flagged positive for colistin resistance by the system were further tested according to European Committee on Antimicrobial Susceptibility Testing (EUCAST) clinical breakpoints (version 6.0) [9]. As recommended by EUCAST [10] and the European Centre for Disease Prevention and Control (ECDC) [3], minimal inhibitory concentration (MIC) of colistin was determined by broth microdiluition (UMIC colistine ARNIKA SRL Diagnostic Line, Milano, Italy). The MIC of colistin was 4 mg/L for all the isolates (≤2 susceptible, >2 resistant).

Only blood isolates were further tested: unfortunately, the urine ones, which had a similar resistance profile to the isolates from blood, were not available for investigation.

Whole genome DNA was extracted from each isolate using a QIAamp DNA minikit (Qiagen) following the manufacturer’s instructions, and sequenced using an Illumina Miseq platform with a 2 by 250 paired-end run after Nextera XT paired-end library preparation.

Genome assembly was performed using SPAdes-3.10.1 software. The genomic sequences were submitted to the European Nucleotide Archive (ENA) (accession numbers pending). Multilocus sequence typing (MLST) profiles were obtained in silico by analysing appropriate gene variants for each genome, using an in-house Perl script, based on the Achtman MLST scheme [11]. Analysis of the 7-gene MLST showed that the three isolates belong to three different sequence types: ST131, ST3941 and ST1851 respectively.

All three E. coli isolates obtained from blood were colistin-resistant. We thus searched the genomes for the presence of mcr-1 and mcr-2 genes as both these genes can confer plasmid-mediated resistance to colistin. A Basic Local Alignment Search Tool (BLAST) searches of mcr-1 (plasmid accession number KP347127) and mcr-2 (LT598652) against the three assemblies were performed. For each genome we obtained a best hit for mcr-1 gene with a very low number of nucleotide (nt) differences (2, 0 and 1 nt differences for the ST131, ST3941 and ST1851 strains, respectively) and no best hit for mcr-2. Considering that mcr-1 and mcr-2 gene sequences used in the analysis are very different at nt level (375 nt differences), the results show that all three genomes harboured mcr-1 and none harboured mcr-2.

Discussion

The occurrence of colistin resistance based on the plasmid-encoded mcr-1 gene in Enterobacteriaceae has been described in different European countries since it was first reported in November 2015 [3-8].

To our knowledge, our data show the first three bloodstream infections mediated by mcr-1-encoding E. coli in Italy [12,13]. A limitation of our report is that we did not perform a systematic investigation of all bloodstream infections over a certain period in our hospital and we are thus lacking denominator data that would provide better insight into the frequency of the problem. A study is planned to retrospectively analyse all E. coli strains obtained in the past year in our hospital to complete our data.

All three patients in our case series had underlying oncological diseases with different degrees of severity which would put them at higher risk of sepsis, however not at higher risk of exposure to mcr-1–positive pathogens. None of the patients was previously exposed to colistin. Except for being hospitalised at the same institution at different points in time over a 6-month period, no other epidemiological link could be determined between them. Moreover, the three mcr-1-positive isolates belonged to three different STs, indicating the presence of different colistin-resistant strains.

The first of the three strains belonged to ST131. This ST has been described by Overdevest et al. as an E. coli clone associated with extended-spectrum beta-lactamase (ESBL) production that can colonise patients for prolonged periods, with an estimated half-life of 13 months [14] and by Wang et al. as a prevalent ST in China probably associated with a high risk of dissemination among E. coli [6]. In our patient, the ST131 E. coli did not appear to be more pathogenic.

The ST1851 is a new ST, and the draft genome assembly of the respective E. coli-1851 strain has been deposited at ENA (accession numbers pending).

All three isolates described here showed a favourable susceptibility profile to other classes of antimicrobials and the three bloodstreams infections were rapidly resolved with the chosen empirical therapy. In a recently published article, Poirel et al. [15] describe how not all plasmids with an mcr-1 gene carry other genes encoding resistance to clinically relevant antibiotics, such as β-lactams, aminoglycosides, quinolones, fosfomycin, sulfonamides, and tetracyclines. In 2016, Bernasconi et al. [16] and Prim et al. [17] also reported occurrence of the mcr-1 gene in pathogens without presence of further genes conferring resistance for example to extended-spectrum cephalosphorins or carbapenemase. This fact may account for the positive outcome of the infections described here but on the other side further highlights the importance of horizontal dissemination of mcr-1 gene-related colistin resistance in non-multidrug-resistant (MDR) E. coli isolates of human origin.

The identification of three patients with bloodstream infections caused by different strains of mcr-1–positive E. coli detected within 6 months in a single hospital suggests an important and widespread problem [3]. Furthermore, our findings suggest that the dissemination of mcr-1-positive E. coli in Italy could be underestimated because isolates may be susceptible to other tested antibiotics and screening is often focused on carbapenem-resistant strains only. Moreover, in Italy, where the MDR bacteria are endemic, the acquisition of mcr-1 plasmid-mediated genes by other MDR Enterobacteriaceae could lead to a severe public health concern because it seriously limits treatment options as already reported in 2016 by Di Pilato et al. [18]. Our data further highlight the need of strict surveillance of colistin resistance even in multi-susceptible isolates.


Ethics statement

The study was designed and conducted in accordance with the Helsinki declaration. This study was performed according to the guidelines of the Fondazione IRCCS Policlinico San Matteo Institutional Review Board for the use of biological specimens for scientific purposes in keeping with Italian law (art.13 D.Lgs 196/2003).

Acknowledgements

The authors acknowledge Dr D. Sassera for manuscript revision, Dr M. Vecchia, Dr M. Bonfichi, Dr L. Pasturenzi for clinical information.

Conflict of interest

None declared.

Authors’ contributions

Wrote the manuscript: MC, BM; performed laboratory investigations: PC, MC, BM; genome sequencing and sequences analysis: ES, CF, FC; revised the manuscript: PC, PM.


References

  1. Liu YY, Wang Y, Walsh TR, Yi LX, Zhang R, Spencer J,  et al.  Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study. Lancet Infect Dis. 2016;16(2):161-8. DOI: 10.1016/S1473-3099(15)00424-7 PMID: 26603172

  2. Li J, Nation RL, Turnidge JD, Milne RW, Coulthard K, Rayner CR,  et al.  Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect Dis. 2006;6(9):589-601. DOI: 10.1016/S1473-3099(06)70580-1 PMID: 16931410

  3. European Centre for Disease Prevention and Control (ECDC). Plasmid-mediated colistin resistance in Enterobacteriaceae. Stockolm: ECDC; 2016. Available from: http://ecdc.europa.eu/en/publications/Publications/enterobacteriaceae-risk-assessment-diseases-caused-by-antimicrobial-resistant-microorganisms-europe-june-2016.pdf

  4. Walkty A, Karlowsky JA, Adam HJ, Lagacé-Wiens P, Baxter M, Mulvey MR,  et al.  Frequency of MCR-1-mediated colistin resistance among Escherichia coli clinical isolates obtained from patients in Canadian hospitals (CANWARD 2008-2015). CMAJ Open. 2016;4(4):E641-5. DOI: 10.9778/cmajo.20160080 PMID: 28018876

  5. Quan J, Li X, Chen Y, Jiang Y, Zhou Z, Zhang H, et al. Prevalence of mcr-1 in Escherichia coli and Klebsiella pneumoniae recovered from bloodstream infections in China: a multicentre longitudinal study. Lancet Infect Dis. 2017;17(4):400-10. PMID: 28139430

  6. Wang Y, Tian GB, Zhang R, Shen Y, Tyrrell JM, Huang X,  et al.  Prevalence, risk factors, outcomes, and molecular epidemiology of mcr-1-positive Enterobacteriaceae in patients and healthy adults from China: an epidemiological and clinical study. Lancet Infect Dis. 2017;17(4):390-9. DOI: 10.1016/S1473-3099(16)30527-8 PMID: 28139431

  7. Nordmann P, Lienhard R, Kieffer N, Clerc O, Poirel L. Plasmid-Mediated Colistin-Resistant Escherichia coli in Bacteremia in Switzerland.Clin Infect Dis. 2016;62(10):1322-3. DOI: 10.1093/cid/ciw124 PMID: 26936673

  8. Skov RL, Monnet DL. Plasmid-mediated colistin resistance (mcr-1 gene): three months later, the story unfolds.Euro Surveill. 2016;21(9):30155. DOI: 10.2807/1560-7917.ES.2016.21.9.30155 PMID: 26967914

  9. European Committee on Antimicrobial Susceptibility Testing (EUCAST). Breakpoint tables for interpretation of MICs and zone diameters. Version 6.0, valid from 2016-01-01. Available from: http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/v_6.0_Breakpoint_table.pdf

  10. European Committee on Antimicrobial Susceptibility Testing (EUCAST). Recommendations for MIC determination of colistin (polymyxin E). As recommended by the joint CLSI-EUCAST Polymyxin Breakpoints Working Group. Växjö: EUCAST; 22 Mar 2016. Available from: http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/General_documents/Recommendations_for_MIC_determination_of_colistin_March_2016.pdf

  11. Wirth T, Falush D, Lan R, Colles F, Mensa P, Wieler LH,  et al.  Sex and virulence in Escherichia coli: an evolutionary perspective. Mol Microbiol. 2006;60(5):1136-51. DOI: 10.1111/j.1365-2958.2006.05172.x PMID: 16689791

  12. Cannatelli A, Giani T, Antonelli A, Principe L, Luzzaro F, Rossolini GM. First Detection of the mcr-1 Colistin Resistance Gene in Escherichia coli in Italy.Antimicrob Agents Chemother. 2016;60(5):3257-8. DOI: 10.1128/AAC.00246-16 PMID: 26976865

  13. Giufrè M, Monaco M, Accogli M, Pantosti A, Cerquetti M, PAMURSA Study Group. Emergence of the colistin resistance mcr-1 determinant in commensal Escherichia coli from residents of long-term-care facilities in Italy.J Antimicrob Chemother. 2016;71(8):2329-31. DOI: 10.1093/jac/dkw195 PMID: 27261262

  14. Overdevest I, Haverkate M, Veenemans J, Hendriks Y, Verhulst C, Mulders A,  et al.  Prolonged colonisation with Escherichia coli O25:ST131 versus other extended-spectrum beta-lactamase-producing E. coli in a long-term care facility with high endemic level of rectal colonisation, the Netherlands, 2013 to 2014. Euro Surveill. 2016;21(42):30376. DOI: 10.2807/1560-7917.ES.2016.21.42.30376 PMID: 27784530

  15. Poirel L, Jayol A, Nordmann P. Polymyxins: Antibacterial Activity, Susceptibility Testing, and Resistance Mechanisms Encoded by Plasmids or Chromosomes.Clin Microbiol Rev. 2017;30(2):557-96. DOI: 10.1128/CMR.00064-16 PMID: 28275006

  16. Bernasconi OJ, Kuenzli E, Pires J, Tinguely R, Carattoli A, Hatz C,  et al.  Travelers can import colistin resistant Enterobacteriaceae, including those possessing the plasmid-mediated mcr-1 gene. Antimicrob Agents Chemother. 2016;60(8):5080-4. DOI: 10.1128/AAC.00731-16 PMID: 27297483

  17. Prim N, Rivera A, Rodríguez-Navarro J, Español M, Turbau M, Coll P,  et al.  Detection of mcr-1 colistin resistance gene in polyclonal Escherichia coli isolates in Barcelona, Spain, 2012 to 2015. Euro Surveill. 2016;21(13):30183. DOI: 10.2807/1560-7917.ES.2016.21.13.30183 PMID: 27055477

  18. Di Pilato V, Arena F, Tascini C, Cannatelli A, Henrici De Angelis L, Fortunato S,  et al.  mcr-1.2, a New mcr Variant Carried on a Transferable Plasmid from a Colistin-Resistant KPC Carbapenemase-Producing Klebsiella pneumoniae Strain of Sequence Type 512. Antimicrob Agents Chemother. 2016;60(9):5612-5. DOI: 10.1128/AAC.01075-16 PMID: 27401575



Back to Table of Contents
Download (pdf)
Next

The publisher’s policy on data collection and use of cookies.

Disclaimer: The opinions expressed by authors contributing to Eurosurveillance do not necessarily reflect the opinions of the European Centre for Disease Prevention and Control (ECDC) or the editorial team or the institutions with which the authors are affiliated. Neither ECDC nor any person acting on behalf of ECDC is responsible for the use that might be made of the information in this journal. The information provided on the Eurosurveillance site is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician. Our website does not host any form of commercial advertisement. Except where otherwise stated, all manuscripts published after 1 January 2016 will be published under the Creative Commons Attribution (CC BY) licence. You are free to share and adapt the material, but you must give appropriate credit, provide a link to the licence, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

Eurosurveillance [ISSN] - ©2007-2016. All rights reserved
 

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.